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Abstract
Background: The high rate of attrition along the care cascade of infection with human immunodeficiency virus
(HIV) results in lost opportunities to provide timely antiretroviral therapy (ART) and to prevent unnecessarily high
mortality. This study aims to assess the effectiveness of a structural intervention, the one-stop (“One4All”) strategy
that streamlines China’s HIV care cascade with the intent to improve testing completeness, ART initiation, viral
suppression, and mortality.
Method: A two-arm, cluster-randomized controlled trial was implemented in twelve county hospitals in Guangxi China
to test the effectiveness of the One4All strategy (intervention arm) compared to the current standard of care (SOC;
control arm). The twelve study hospitals were selected for homogeneity and allocated one-to-one to the intervention
and control arms. All patients screening HIV positive in study hospitals were enrolled. Target study enrollment was 180
participants per arm, 30 participants per hospital. Basic demographic information was collected as well as HIV risk
behavior and route of infection. In intervention hospitals, patients then went on to receive point-of-care CD4 testing
and in-parallel viral load (VL) testing whereas patients in control hospitals progressed through the usual SOC cascade.
The primary outcome measure was testing completeness within 30 days of positive initial HIV screening result. Testing
completeness was defined as receipt of all tests, test results, and post-test counseling. The secondary outcome
measure was ART initiation (receipt of first ART prescriptions) within 90 days of positive initial HIV screening result.
Tertiary outcome measures were viral suppression (≤200 copies/mL) and all-cause mortality at 12 months.
Discussion: We expect that this first-ever, cluster-randomized controlled trial of a bundle of interventions intended to
streamline the HIV care cascade in China (the One4All strategy) will provide strong evidence for the benefit of
accelerating diagnosis, thorough clinical assessment, and ART initiation via an optimized HIV care cascade. We
furthermore anticipate that this evidence will be valuable to policymakers looking to elevate China’s overall HIV/AIDS
response to meet the UNAIDS 90-90-90 targets and the broader, global goal of eradication of the HIV/AIDS epidemic.
Trial registration: ClinicalTrials.gov #NCT02084316. (Registered on March 7, 2014)
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Background
In both resource-rich and resource-limited settings alike,
patients are commonly lost at each step along the care
cascade of infection with human immunodeficiency virus
(HIV) that causes acquired immunodeficiency syndromes
(AIDS) [1]. In China, the current standard-of-care (SOC)
patient pathway from screening HIV-positive to initiating
antiretroviral therapy (ART) involves multiple hospital
visits, during which patients submit to several separate
blood draws, and then experience protracted waiting
periods before they are notified of results. This causes
substantial loss to follow-up, delays in diagnosis, clinical
assessments that are incomplete, and ART initiation at
later stages of disease progression [2, 3]. Recent studies
have indicated that, in some parts of China, only approxi-
mately 43% of those who screen HIV-positive in hospital
settings received confirmatory testing [3], and only 57% of
those confirmed HIV-positive received CD4 testing within
6 months [4]. Since CD4 count has been used to deter-
mine eligibility for ART, it has been estimated that nearly
80% of those with newly-identified HIV infection, who
were ART-eligible, were not initiated on ART in a timely
fashion. Unfortunately, these missed opportunities for
engagement in the HIV care cascade has ultimately trans-
lated to preventable high mortality [2, 5].
Although it seems obvious, it is critically important that
people living with HIV (PLHIV) step through all the mile-
stones on the HIV care cascade in order for to fully realize
the benefits of ART—they must become aware of their
HIV-positive status, receive a diagnosis and clinical assess-
ment, attend counseling, enroll in care and initiate ART,
and adhere to their treatment regimens and follow-up
schedules [1, 6]. However, merely accessing these services,
and sequentially stepping through the process, may not be
enough. Increasing evidence has highlighted the import-
ance of the timing in which these services are accessed.
Two large, recently-completed clinical trials, TEMPRANO
and START, have provided evidence of benefit in not wait-
ing to treat HIV infection until evidence of disease progres-
sion is present in the form of symptoms or low CD4 count
[7, 8]. This benefit of reduced clinical disease progression,
as well as decreased overall mortality, has since been con-
firmed in other settings, including China [2]. In response,
the World Health Organization (WHO) modified its guide-
lines in 2015, recommending immediate ART initiation for
all PLHIV regardless of symptoms or CD4 count [9].
The strong evidence for the clinical benefit of immediate
ART for PLHIV [7, 8], taken together with the previously-
identified public health benefit in the form of reduced
transmission rates [10, 11], meant that optimization of the
HIV care cascade was even more important than previously
thought. A number of studies in a variety of settings have
been designed to examine a range of interventions intended
to improve the HIV care cascade. Thus far, majority of
these types of studies in low- and middle-income settings
have been in Sub-Saharan Africa [12]. However, in general,
they have not followed participants beyond the pre-ART
period and have not evaluated the effectiveness of multiple
interventions implemented as a package [13–19]. One such
study has recently been completed and published in China,
providing evidence that a simplified test-and-treat interven-
tion can improve both HIV care cascade retention and time
to ART initiation [2].
Objective and outcomes
The objective of the present clinical trial was to evaluate a
streamlined pathway for patients from screening HIV-
positive to initiating ART, testing the effectiveness of a
structural intervention—called the one-stop (“One4All”)
strategy. This experimental strategy consisted of a new
algorithm incorporating rapid, point-of-care (POC) HIV
screening and CD4 testing, and in-parallel plasma viral load
(VL) testing to promote fast and complete HIV diagnosis
and staging, followed by immediate counseling and ART
initiation for eligible patients. The One4All intervention
was compared to the current SOC (control arm), and four
outcomes were assessed:
1. Testing completeness within 30 days of HIV-positive
screening (primary)
2. ART initiation within 90 days of HIV-positive
screening (secondary)
3. Viral suppression (≤200 copies/mm3) at 12 months
after HIV-positive screening (tertiary)
4. All-cause mortality at 12 months after HIV-positive
screening (tertiary)
Method
Design
A cluster-randomized trial was designed as diagrammed in
Fig. 1. Hospitals were the unit of randomization and twelve
similar county-level hospitals were allocated one-to-one to
the intervention and control arms of the study. The efficacy
of the intervention was determined by comparison to the
current standard of care (SOC, control arm) at 30 days,
90 days, and 12 months.
Setting
The setting for this study was county hospitals in Guangxi
Zhuang Autonomous Region (hereafter referred to as
Guangxi). In 2011, Guangxi reported the second highest
cumulative number of HIV/AIDS cases in China, the
highest number of newly-reported HIV/AIDS cases, the
highest number of newly-reported AIDS cases, and the
highest number of AIDS-related deaths [5]. As shown in
Fig. 2, a broad range of characteristics of potential county-
level hospitals in Guangxi were examined. The hospitals
Mao et al. BMC Health Services Research  (2017) 17:397 Page 2 of 9
included in the study were selected based on their homo-
geneity across these characteristics.
Allocation and blinding
The twelve selected study hospitals were stratified by
historical rates of testing completeness followed by post-
test counseling during the first six months of 2013 prior
to being allocated to the intervention or control study
arms. Eight hospitals were within the low historical testing
completion stratum of <20%, and these eight hospitals
were randomized, four into the intervention arm and four
into the control arm. Four hospitals were within the high
historical testing completion stratum of ≥20%, and these
four hospitals were randomized, two into the intervention
arm and two into the control arm. All patients who
screened HIV-positive in the six intervention hospitals
received the One4All intervention and all patients who
screened HIV-positive in the six control hospitals during
the same study period received SOC services. There was
no blinding required since the unit of randomization was
the study hospital and each hospital only offered the HIV
care cascade it was assigned during randomization—SOC
or One4All.
Participants and recruitment
Study eligibility criteria were: [a] being 18 years of age or
older, [b] having a positive result on an HIV enzyme
immunoassay (EIA) screening test, [c] seeking care in a
study hospital, either inpatient or outpatient, and [d] resid-
ing or intending to reside within the study catchment area.
Study exclusion criteria were: [a] having previously received
confirmation of HIV infection in any setting, [b] being a
prisoner or detainee at time of screening, or [c] being a
pregnant woman.
No special strategies to ensure adequate participant
enrollment were employed. All patients who were found
to be eligible were enrolled in the study. After enrollment,
basic demographic information was collected. Information
on self-reported risk behavior and route of HIV acquisi-
tion were also collected.
Ethics
The protocol and consent process were reviewed and
approved by the US National Institutes of Health (NIH),
National Institute on Drug Abuse (NIDA) Protocol
Review Board and Data and Safety Monitoring Board, as
well as respective institutional review boards (IRBs) of the
University of California, Los Angeles (UCLA) and the
County Hospitals (N=12)
Randomization
Control Arm
Standard of Care (SOC)
County Hospitals (n=6)
Target Enrollment = 
30 participants per hospital ×
6 hospitals = 180 participants
Intervention Arm
One4All Test Intervention
County Hospitals (n=6)
Target Enrollment = 
30 participants per hospital ×
6 hospitals = 180 participants
Assessment:
• 30 days
• 90 days
• 12 months
Baseline Assessment
Fig. 1 Diagram of study design. This diagram illustrates the cluster-
randomized controlled study design with one-to-one allocation of
twelve county-level hospitals to either the control arm (current
standard of care [SOC]) or the intervention arm (the “One4All” strategy
intended to streamline the HIV care cascade)
Fig. 2 List of Hospital Characteristics. The eighteen different
characteristics listed here were examined in the process of assessing
candidate county-level hospitals in Guangxi, China. The final twelve
study hospitals were selected based upon homogeneity across
these characteristics
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National Center for AIDS/STD Control and Prevention
(NCAIDS), China Center for Disease Control and Preven-
tion (CDC).
Individual informed consent was not obtained. Study
information was shared with participants and participants
were given opportunities ask questions. While participants
could refuse to participate, or to share their data, their
enrollment still counted toward the total number of study
participants. No study-related reimbursement for partici-
pants was provided.
All patient data were protected and kept confidential
according to standard procedures present within China’s
healthcare system. Participant data extracted from hospital
records, and from China’s National HIV/AIDS Comprehen-
sive Response Information Management System (CRIMS,
which has been described elsewhere) [20], were assigned
trial-specific participant identification numbers and then
otherwise de-identified prior to use to protect participant
privacy.
Sample size
A minimum sample size of 180 participants per arm, across
12 clusters (or 30 participants per cluster) was selected. This
sample size was expected to achieve 93% power based on a
one-sided test (at alpha = 0.05) to detect a difference be-
tween the group proportions of 0.28, where under the alter-
native hypothesis the One4All arm proportion was assumed
to be 0.50 and the control arm proportion was assumed to
be 0.22. This calculation assumed an intra-class correlation
(ICC) within hospitals of 0.082 based on preliminary data.
Although 30 participants per cluster (or hospital) was the
target, it was expected that some hospitals would enroll
participants more quickly than others. Therefore, a final
study population of greater than 180 participants per arm
was anticipated as enrollment at all hospitals remained open
until the last hospital met its 30-participant goal.
Intervention
A high-level overview of the HIV care cascade in SOC
(control arm) and One4All (intervention arm) hospitals is
depicted in Fig. 3. The One4All test intervention included
rapid, POC HIV EIA screening and CD4 testing, with in-
parallel VL testing. This strategy was intended to promote
rapid and complete diagnostic assessment and accelerate
time to ART initiation for those deemed ART eligible.
The ART eligibility threshold at the time of this study was
CD4 count ≤350 cells/mm3. Each of the steps in the HIV
care cascade up to assessment of ART eligibility are
described in detail below for both the SOC condition and
the One4All condition. In both care cascades, all partici-
pants received post-test counselling each and every time
they received test results.
HIV Screening
In SOC study hospitals, the Wantai Screening HIV (1 + 2)
Ag&Ab EIA (Beijing Wantai Manufacturer of Infectious
Diseases Diagnostics) was used as the initial screening test
followed by two different EIAs that varied between sites.
In One4All study hospitals, the first HIV screening test
was the also the Wantai Screening HIV (1 + 2) Ag&Ab
EIA. The second and the third EIAs were the Determine
HIV-1/2® rapid test (Abbott Laboratories) and the InTec
HIV rapid test (Xiameng InTec Products).
HIV Confirmation
In SOC study hospitals, an additional blood sample was
collected immediately following screening or on a subse-
quent study hospital visit. The sample was sent to the local
city CDC laboratory for Western blot (WB) confirmatory
testing according to usual practice. As confirmatory testing
required approximately 10 to 15 days to be completed,
participants typically had to be contacted and asked to
return to the study hospital to receive their results.
In One4All study hospitals, WB was not used for con-
firmatory testing. Rather, VL testing served as the confirma-
tory test (see below).
CD4 Count
In SOC study hospitals, participants were asked to return
to the study hospital for another blood draw for CD4
testing after they were notified that the result of their
confirmatory testing was positive. Blood specimens were
again sent to the city CDC laboratory, this time for CD4
testing. CD4 testing also required approximately 10 to
Fig. 3 Illustration of Intervention and Control Conditions. This
illustration depicts the differences in the HIV care cascade between
control (standard of care [SOC]) and intervention (“One4All” strategy)
study arms. In the SOC condition, HIV care cascade steps 2, 3, 4, 5, and
7 are all consolidated into a single step 2 in the One4All condition
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15 days to complete. Once CD4 test results were available,
participants were again asked to return to be notified.
In One4All study hospitals, POC CD4 testing was per-
formed in the study hospital with a POC Pima™ CD4
Analyzer (Alere Healthcare, USA) using whole blood
samples. Results were available within 30 min. Partici-
pants were notified of their results as soon as possible,
but no later than the next day if they had left the study
hospital during the test.
Viral load
In SOC study hospitals, VL testing was conducted ap-
proximately one year after ART initiation. Participants
were asked to return to the study hospital for blood
sample collection. Blood samples were sent to the
provincial CDC laboratory for plasma VL testing, which
required 10 to 15 days to complete. Participants were
contacted and asked to return to the study hospital to
receive VL testing results once they were available.
In One4All study hospitals, blood samples for VL testing
were collected immediately following receipt of positive
screening results, at the same time as the blood draw for
CD4 testing (see above). VL testing was conducted again
after one year. Plasma VL testing itself was conducted in
the same manner as in SOC study hospitals—samples were
sent to the provincial CDC laboratory, plasma VL testing
required 10 to 15 days, and participants asked to return to
the study hospital to receive VL test results.
This intervention condition posed no specific safety risk
to participants. In comparison to SOC study hospitals, the
HIV care cascade in One4All study hospitals involved
fewer blood draws and there was no increase in the
volume of blood drawn or the typical risk associated with
blood draws.
Outcomes
The primary outcome measure was the proportion of
participants who achieved testing completeness and re-
ceived test results and post-test counseling within 30 days
of positive screening. Testing completeness was defined as
completion of three required components: 1) initial HIV
screening (one to two tests in One4All and two to four in
SOC), 2) CD4 testing, and 3) confirmatory HIV test-
ing—WB in the SOC arm, or VL in the One4All arm.
“Success” was defined as completion of all three required
tests and notification of test result along with receipt of
counseling after each test. Success was compared at 30 days
after initial HIV-positive screening. The secondary outcome
measure was the proportion of participants who initiated
ART within 90 days from the date of HIV-positive screen-
ing. ART-initiation was defined as the receipt of the first
ART prescription. Tertiary outcomes included the propor-
tion of participants who achieved viral suppression (≤200
copies/mm3) and mortality at 12 months. Mortality was
assessed as the number of reported deaths divided by the
number of patients enrolled.
Aside from these main outcome measures, three other
measures were pre-specified. For the primary outcome, two
further analyses were planned: time from initial positive
HIV screen to success, not restricted to the 30-day window,
compared between control and intervention arms, and suc-
cess at 45, 60, and 90 days, also compared between control
and intervention arms. For the secondary outcome, one
further analysis was planned: time from initial positive HIV
screen to ART initiation, not restricted to the 90-day win-
dow, compared between control and intervention arms.
Timeline
A general study timeline is depicted in Fig. 4. Significant
preparation prior to trial commencement was required
and included completion of the IRB processes at multiple
institutions, baseline hospital assessment, selection, and
allocation, and staff training and site preparation. This
phase was expected to take approximately 14 months.
Once the study began, implementation and enrollment
were anticipated to take 9 months, and follow-up a further
12 months. After trial completion, data analysis and
reporting was planned for the following 12 months.
Data collection, management, and monitoring
Baseline assessment information, including participant
contact and demographic information, laboratory screening
results and dates, test result notification dates, and post-test
counseling dates were all collected using case reporting
forms (CRFs). CRF data were stored in a web-based
database constructed specifically for the study. This
database served as the centralized location for electronic
storage of all study-related data. Study-related data from
each hospital system was retrieved weekly and uploaded to
this study database.
To supplement the data contained in the study-specific
database, records were extracted from CRIMS [20]. Each
county hospital nationwide, including all participating study
hospitals, have unique identification codes in CRIMS to
facilitate extraction of all data on HIV cases identified at
study hospitals.
A centralized Data and Statistics Team (DST) was
responsible for the validation of the web-based study data-
base, retrieval of study hospital data, data extraction from
CRIMS, merger of the two datasets into one, assurance of
data integrity and security, and development and delivery
of training for participating hospital and CDC staff
members on applicable data management procedures.
Data analysis
To adjust for both the clustering effect of hospitals (with
hospital as a random effect to account for the ICC) and
baseline participant-level and hospital-level confounding
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factors, analysis of the primary outcome measure was
performed using G-side GLIMMIX modeling. Participant-
level factors included in the model were age, gender,
ethnicity, education, occupation, marital status, transmis-
sion route, and treatment setting (inpatient/outpatient),
and hospital-level factors included baseline test comple-
tion rate prior to randomization. To assess the consistency
of the primary outcome results, a Chi-square test adjusted
for clustering was also used to measure the association
between treatment arm and the primary outcome [21],
although this method does not account for baseline
confounders. Secondary analyses of the primary outcome
measure were performed as a waiting time analysis
examining time from initial positive screen to success. For
this waiting time analysis, participants who did not meet
the testing success criteria were censored at their last
follow-up dates. Kaplan-Meier curves were used to display
differences over time from screening to testing and coun-
seling completeness.
In comparing differences in baseline characteristics
between the two arms, a Chi-square test adjusted for cluster-
ing was performed for binary variables. When baseline
categorical variables had more than 2 responses, an adjusted
p-value was calculated by referring the observed (un-
adjusted) Chi-square value to the distribution of Chi-square
values obtained by randomly permuting observed treatments
over hospitals, with the adjusted p-value defined as the
proportion of 'permuted' Chi-square values at least as large
as observed. To test between-arm differences in continuous
data, a t-test adjusted for clustering was performed [21].
Analytical methods and the adjustment for clustering
and covariates effects used in the analysis of the primary
outcome were also applied to the ART initiation second-
ary outcome and viral suppression tertiary outcome. As
with the secondary analysis of the primary outcome,
Kaplan-Meier analyses were also performed for time to
initiation of ART, outside the 90-day window, and time to
death. In addition, for the mortality outcome, a random
effects Cox (shared frailty) model accounting for the hos-
pital clustering effect was used to calculate the interven-
tion effect on the hazard ratio (HR) of death while also
controlling for other covariates. Adjustments to p-values
and confidence intervals for multiple testing and multiple
comparisons were not performed. All data analyses were
performed using SAS software (SAS Institute, Inc., USA).
Dissemination
The trial is registered with ClinicalTrials.gov (#NCT02
084316) and the original protocol has been published on
CTNDisseminationLibrary.org. The dataset is available
upon request to the corresponding author.
Discussion
To our knowledge this is the first controlled clinical trial to
examine a bundle of interventions intended to improve
multiple points in China’s HIV care cascade. A notable
strength of this study lies in the rigor with which the effect-
iveness of the One4All strategy was tested. We expected
that it would provide strong evidence in support of a
streamlined HIV care cascade that accelerates diagnosis,
Fig. 4 Timeline of the Study. The study was expected to require approximately 14 months for pre-implementation preparation (i.e. IRB preparation,
submission, review, and approval; baseline hospital assessment, selection, and allocation; and staff training and site preparation). Implementation and
enrollment were expected to take a further 9 months, and follow-up required a subsequent 12-month period. Finally, data analysis and reporting were
expected to require another 12 months. (institutional review board [IRB], antiretroviral therapy [ART])
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complete clinical assessment, and treatment initiation
having a significant clinical benefit over the current SOC.
With growing global evidence of the clear benefits of
immediate ART for all PLHIV, both for the purposes of
treatment of HIV infection and of prevention of HIV trans-
mission [7, 8, 10], HIV/AIDS programs around the world
must place renewed focus on optimization of the HIV care
cascade. Worldwide, three out of every five PLHIV have
not accessed ART [22]. Steps must be taken to eliminate
losses to follow-up in the pre-ART period, and to ensure
that all PLHIV receive immediate treatment.
At the time the present study was conducted, China still
had a CD4 count ≤350 cells/mm3 ART eligibility criterion
in place, with exceptions allowed only for PLHIV who
were pregnant or in serodiscordant relationships [23]
Thus, we expected that some participants in our study
could not initiate ART despite being successfully retained
in the pre-ART HIV care cascade. The WHO has since
elevated the CD4 count threshold for ART to CD4 count
≤500 cells/mm3 in 2013 [24], and then abolished it in
2015, now recommending that all PLHIV receive immedi-
ate ART regardless of CD4 count [9]. Two studies in
China have recently examined the benefit of ART initi-
ation for PLHIV who did not meet the ≤350 cells/mm3
threshold. One prospectively examined immediate ART
for all participants regardless of CD4 count [2], the other
retrospectively investigated ART given to PLHIV with
CD4 counts >500 cells/mm3 on an exception basis or as a
part of the NCAIDS-sponsored “Prevention and Treat-
ment of Major Infectious Diseases” project launched in
2012, which consisted of a series of cluster-randomized
controlled trials among key populations. Both studies
found significant improvements in mortality. We envision
the combination of this evidence with the outcome of the
present study supporting the complete replacement of
China’s current SOC HIV care cascade with a new,
streamlined cascade that accelerates diagnosis, complete
clinical assessment, and ART initiation for all PLHIV.
Several important challenges were anticipated prior to
trial commencement. For example, there was known
variability in HIV SOC offered between different counties
in Guangxi. A major cause of poor testing completeness
and treatment initiation in rural Guangxi is disjointed HIV
services as a result of structural and cultural constraints.
County hospitals and CDCs struggle to follow national
guidelines, mainly because of limited laboratory capacity
and complex referral systems between hospitals and CDCs.
The study team debated whether to provide strict guide-
lines and training to control arm study hospitals in an effort
to standardize their current practice and improve homo-
geneity. However, we ultimately decided against tampering
with the control condition, as we determined that a control
comparator that represented the reality of the current
standard HIV care cascade was more valuable than an
artificial ideal control environment we would have created
only for the benefit of the study. Therefore, during our
baseline hospital investigations, the investigators engaged
with hospital leaders and key personnel involved in HIV
care and collected the key characteristics of the routine
practice adopted at each county. A detailed testing to
treatment flowchart was developed for each of the hospi-
tals, documenting the key deviations from national guide-
lines. Then, CRFs were adjusted in order to accurately
reflect the reality of testing and linkage to care procedures
in each hospital.
Another key challenge was in the size of the study. The
study was originally designed to include 24 hospitals (or
clusters), 12 each in the control and intervention arms.
This would have provided adequate power to detect differ-
ences between arms in all four outcomes. However, due to
both the known high degree of variability observed in
SOC services across counties in Guangxi and historically
low numbers of patients screening HIV positive in many
hospitals, not to mention the inherent difficulties with
implementing such a large study, we decided to scale back
the number of hospitals to 12. Although we suspected that
we would still find statistically significant differences in
several of the outcomes, the study was truly only ad-
equately powered to detect between-arm differences in
the primary outcome of testing completeness by 30 days.
As the study included no intervention related to ART
regimen adherence, we anticipated the possibility that we
may find no between-arm differences in achievement of
viral suppression. We chose to define viral suppression as
≤200 copies/mL based on the equipment used for the
study in local laboratories, recognizing that this target was
aggressive. Although above the <50 copies/mL definition
of viral suppression commonly recognized in high-income
settings, it is well below the <1,000 copies/mL threshold
recognized by the WHO as achievement of viral suppres-
sion in low- and middle-income countries such as China.
It is also below the 300 to 500 copies per/mL target com-
monly used by research teams in studies in low- and
middle-income settings [1, 25]. Future studies will need to
examine interventions aimed at improving adherence in
order to promote achievement of viral suppression.
Additionally, with increased numbers of PLHIV on ART,
it will be necessary for China’s public health and health-
care communities to be vigilant in monitoring patients for
treatment failure. This will require substantial improve-
ment of VL testing infrastructure and China should
strongly consider investment in the development and im-
plementation of new POC VL testing technologies, which
further contribute to a streamlined HIV care cascade.
Conclusion
This first-ever, cluster-randomized controlled trial of a
bundle of interventions intended to streamline the HIV
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care cascade in China (the One4All strategy) was
evaluated on four outcomes: testing completeness within
30 days, ART initiation within 90 days, viral suppression
at 12 months, and all-cause mortality at 12 months. We
expect that the outcome of this trial will provide strong
evidence for the benefit of accelerating diagnosis, thor-
ough clinical assessment, and ART initiation via an opti-
mized HIV care cascade such as the One4All strategy.
Furthermore, we anticipate that this evidence taken to-
gether with the strong, new evidence of both treatment
and prevention benefits of immediate ART for all PLHIV
regardless of CD4 count [7, 8, 10], will compel careful
consideration by policymakers in China and other, simi-
lar low- and middle-income countries. HIV care cascade
optimization is a critical strategy for meeting the
UNAIDS 90-90-90 targets [26], and will be required for
the eventual eradication of the HIV epidemic.
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